Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Equillium Inc Market Cap
Based on ratings from 4 stock analysts, the Equillium Inc stock price is expected to increase by 376.19% in 12 months. This is calculated by using the average 12-month stock price forecast for Equillium Inc. The lowest target is $2 and the highest is $5. Please note analyst price targets are not guaranteed and could be missed completely.
About 4 Wall Street analysts have assigned EQ 3 buy ratings, 1 hold ratings, and 0 sell ratings. This means that analysts expect Equillium Inc to outperform the market. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on EQ. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of EQ.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Catherine Novack Jones Trading | Hold | Downgrade | Nov 1, 2024 | |
| Raghuram Selvaraju HC Wainwright & Co. | Buy | $5 | Reiterates | Aug 19, 2024 |
| Raghuram Selvaraju HC Wainwright & Co. | Buy | $5 | Reiterates | Jun 5, 2024 |
| Raghuram Selvaraju HC Wainwright & Co. | Buy | $5 | Reiterates | May 17, 2024 |
| Raghuram Selvaraju HC Wainwright & Co. | Buy | $5 | Maintains | Apr 2, 2024 |
| Raghuram Selvaraju HC Wainwright & Co. | Buy | $4 | Maintains | Dec 26, 2023 |
| Raghuram Selvaraju HC Wainwright & Co. | Buy | $4.5 | Maintains | Nov 13, 2023 |
| Emma Nealon Cantor Fitzgerald | Overweight | $2.8 | Reiterates | Aug 14, 2023 |
| Raghuram Selvaraju HC Wainwright & Co. | Buy | $5.5 | Reiterates | Aug 14, 2023 |
HC Wainwright& Co. | Buy | Reiterates | Aug 14, 2023 | |
| Raghuram Selvaraju HC Wainwright & Co. | Buy | $5.5 | Reiterates | May 15, 2023 |
| Raghuram Selvaraju HC Wainwright & Co. | Buy | $5.5 | Maintains | May 1, 2023 |
| Dae Gon Ha Stifel | Buy | $7 | Maintains | Mar 24, 2023 |
| Thomas Smith SVB Leerink | Outperform | $7 | Maintains | Feb 8, 2023 |
| Raghuram Selvaraju HC Wainwright & Co. | Buy | $20 | Maintains | Sep 27, 2022 |
| Thomas Smith SVB Leerink | Outperform | $12 | Maintains | Sep 8, 2022 |
| Raghuram Selvaraju HC Wainwright & Co. | Buy | $15 | Maintains | Mar 24, 2022 |
| Thomas Smith SVB Leerink | Outperform | $14 | Maintains | Jan 5, 2022 |
Cantor Fitzgerald | Overweight | Initiates | Sep 15, 2021 | |
JonesTrading | Buy | Initiates | Mar 3, 2021 |
When did it IPO
2018
Staff Count
45
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Mr. Bruce D. Steel C.F.A.
Market Cap
$26.0M
In 2023, EQ generated $36.1M in revenue, which was a increase of 128.97% from the previous year. This can be seen as a signal that EQ's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Wed, 13 Nov 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Equillium, Inc. (Nasdaq: EQ) reported Q3 2024 financial results and announced the termination of its partnership with Ono Pharmaceutical after securing non-dilutive financing.
Why It Matters - Equillium's financial results and the end of its partnership with Ono Pharmaceutical signal potential shifts in funding and strategic direction, impacting future growth prospects and investor confidence.
Wed, 13 Nov 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Equillium, Inc. (Nasdaq: EQ) will present at the Stifel Healthcare Conference on November 18-19, 2024, discussing its clinical programs and the Phase 3 EQUATOR study of itolizumab.
Why It Matters - Equillium's presentation at the Stifel Healthcare Conference may highlight progress in its Phase 3 EQUATOR study, potentially influencing investor sentiment and stock performance.
Tue, 12 Nov 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Equillium Inc. (Nasdaq: EQ) presented a poster at the Society for Immunotherapy of Cancer meeting, showcasing data on its immunobiology-based therapeutics for autoimmune disorders.
Why It Matters - Equillium's presentation at a prominent immunotherapy conference highlights potential advancements in their drug pipeline, which could influence stock performance and investor confidence.
Wed, 06 Nov 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - Equillium (EQ) may lack the necessary factors for a potential earnings beat in its upcoming report, indicating possible challenges ahead for investors.
Why It Matters - Equillium's lack of key factors for an earnings beat may lead to disappointing results, potentially impacting stock performance and investor sentiment.
Thu, 31 Oct 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Equillium Inc. (Nasdaq: EQ) announced that Ono Pharmaceutical has opted not to acquire its rights to itolizumab. The decision is unrelated to clinical data.
Why It Matters - Equillium's loss of a potential partnership with Ono could impact its funding and development plans, raising concerns about its ability to advance its therapies, affecting investor confidence.
Mon, 07 Oct 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Equillium Inc. (Nasdaq: EQ) announced an abstract acceptance for a poster presentation at the Society for Immunotherapy of Cancer meeting in Houston from November 6-10, 2024.
Why It Matters - Equillium's abstract acceptance for a major immunotherapy conference highlights its research credibility, potentially boosting investor confidence and influencing stock performance.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
